BRIEF-FDA Expands U.S. Age Indication For EVO ICL

+0.29%

STAAR Surgical Company

STAA

17.52

+0.29%

Feb 17 (Reuters) - STAAR Surgical Co STAA.O:

FDA EXPANDS U.S. AGE INDICATION FOR EVO ICL AS LONG-TERM SAFETY DATA REINFORCES MARKET SHIFT AWAY FROM LASER VISION CORRECTION
STAAR SURGICAL CO - FDA EXTENDS EVO ICL USE TO PATIENTS 21-60 YEARS OLD

Source text: ID:nBw1pM85Va

Further company coverage: STAA.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.